Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases

Archive ouverte

Song, Feizhi | Kovac, Valerija | Mohammadi, Behnam | Littau, Jessica, L. | Scharfenberg, Franka | Matamoros Angles, Andreu | Vanni, Ilaria | Shafiq, Mohsin | Orge, Leonor | Galliciotti, Giovanna | Djakkani, Salma | Linsenmeier, Luise | Černilec, Maja | Hartman, Katrina | Jung, Sebastian | Tatzelt, Jörg | Neumann, Julia, E. | Damme, Markus | Tschirner, Sarah, K. | Lichtenthaler, Stefan F | Ricklefs, Franz, L | Sauvigny, Thomas | Schmitz, Matthias | Zerr, Inga | Puig, Berta | Tolosa, Eva | Ferrer, Isidro | Magnus, Tim | Rupnik, Marjan, S. | Sepulveda-Falla, Diego | Matschke, Jakob | Šmid, Lojze, M. | Bresjanac, Mara | Andreoletti, Olivier | Krasemann, Susanne | Foliaki, Simote, T. | Nonno, Romolo | Becker-Pauly, Christoph | Monzo, Cecile | Crozet, Carole | Haigh, Cathryn, L. | Glatzel, Markus | Curin Serbec, Vladka | Altmeppen, Hermann

Edité par CCSD ; Springer Verlag -

International audience. Proteolytic cell surface release (‘shedding’) of the prion protein (PrP), a broadly expressed GPI-anchored glycoprotein, by the metalloprotease ADAM10 impacts on neurodegenerative and other diseases in animal and in vitro models. Recent studies employing the latter also suggest shed PrP (sPrP) to be a ligand in intercellular communication and critically involved in PrP-associated physiological tasks. Although expectedly an evolutionary conserved event, and while soluble forms of PrP are present in human tissues and body fluids, for the human body neither proteolytic PrP shedding and its cleavage site nor involvement of ADAM10 or the biological relevance of this process have been demonstrated thus far. In this study, cleavage site prediction and generation (plus detailed characterization) of sPrP-specific antibodies enabled us to identify PrP cleaved at tyrosin 226 as the physiological and apparently strictly ADAM10-dependent shed form in humans. Using cell lines, neural stem cells and brain organoids, we show that shedding of human PrP can be stimulated by PrP-binding ligands without targeting the protease, which may open novel therapeutic perspectives. Site-specific antibodies directed against human sPrP also detect the shed form in brains of cattle, sheep and deer, hence in all most relevant species naturally affected by fatal and transmissible prion diseases. In human and animal prion diseases, but also in patients with Alzheimer`s disease, sPrP relocalizes from a physiological diffuse tissue pattern to intimately associate with extracellular aggregated deposits of misfolded proteins characteristic for the respective pathological condition. Findings and research tools presented here will accelerate novel insight into the roles of PrP shedding (as a process) and sPrP (as a released factor) in neurodegeneration and beyond.

Suggestions

Du même auteur

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias.

Archive ouverte | Llorens, Franc | CCSD

International audience. BACKGROUND: YKL-40 (also known as Chitinase 3-like 1) is a glycoprotein produced by inflammatory, cancer and stem cells. Its physiological role is not completely understood but YKL-40 is elev...

Complement 3+-astrocytes are highly abundant in prion diseases, but their abolishment led to an accelerated disease course and early dysregulation of microglia

Archive ouverte | Hartmann, Kristin | CCSD

International audience

Cytoskeleton-Associated Risk Modifiers Involved in Early and Rapid Progression of Sporadic Creutzfeldt-Jakob Disease

Archive ouverte | Zafar, Saima | CCSD

Human samples from the Institute of Neuropathology Brain Bank (HUB-ICO-IDIBELL Biobank) and Biobank of Hospital Clinic-IDIBAPS were obtained following the Spanish legislation (Ley de la Investigación Biomédica 2013 and Real Decret...

Chargement des enrichissements...